Cannabis use may alter psychosis severity in methamphetamine users
NCT ID NCT07459270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 90 people hospitalized with methamphetamine-induced psychotic disorder, comparing those who have also used cannabis in their lifetime to those who have not. Researchers will assess psychiatric symptoms, insight, addiction severity, and sleep quality weekly for eight weeks. The goal is to see if cannabis use influences the severity and course of psychosis, and to identify other factors that may play a role.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors understand how cannabis use changes the course of methamphetamine-induced psychosis, leading to better treatment approaches.
What could go wrong
This is an observational study that has not yet started recruiting. It only looks at factors, not a treatment, so it cannot directly improve outcomes. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANNABIS USE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Elazığ Mental Health and Diseases Hospital
Elâzığ, Elâzığ, 23200, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••